Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Type 2 diabetes is characterized by insulin resistance and a progressive loss of β-cell function induced by a combination of both β-cell loss and impaired insulin secretion from remaining β-cells. Here, we review the fate of the β-cell under chronic hyperglycaemic conditions with regard to β-cell mass, gene expression, hormone content, secretory capacity and the ability to de- or transdifferentiate into other cell types. We compare data from various in vivo and in vitro models of diabetes with a novel mouse model of inducible, reversible hyperglycaemia (βV59M mice). We suggest that insulin staining using standard histological methods may not always provide an accurate estimation of β-cell mass or number. We consider how β-cell identity is best defined, and whether expression of transcription factors normally found in islet progenitor cells, or in α-cells, implies that mature β-cells have undergone dedifferentiation or transdifferentiation. We propose that even in long-standing diabetes, β-cells predominantly remain β-cells-but not as we know them.

Original publication

DOI

10.1111/dom.12732

Type

Journal article

Journal

Diabetes Obes Metab

Publication Date

09/2016

Volume

18 Suppl 1

Pages

102 - 109

Keywords

dedifferentiation, diabetes, insulin content, transdifferentiation, β-cell, Animals, Cell Dedifferentiation, Cell Transdifferentiation, Diabetes Mellitus, Type 2, Glucagon-Secreting Cells, Humans, Hyperglycemia, In Vitro Techniques, Insulin, Insulin-Secreting Cells, Mice, Stem Cells